Corrigendum to “Small interfering RNA targeting ILK inhibits metastasis in human tongue cancer cells through repression of epithelial-to-mesenchymal transition” [Exp. Cell Res., 319 (2013): 2058–2072, (S0014482713002206), (10.1016/j.yexcr.2013.05.014)];Small interfering RNA targeting ILK inhibits metastasis in human tongue cancer cells through repression of epithelial-to-mesenchymal transition

Experimental Cell Research

Volumn 319, Issue 13, 2013, Pages 2058-2072

  Xing, Yu ^a   Qi, Jin ^a   Deng, Shixiong ^a   Wang, Cheng ^a   Zhang, Luyu ^a   Chen, Junxia ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition (EMT); Integrin linked kinase; Metastasis; Tongue cancer cells

Indexed keywords

GELATINASE A; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA; INTEGRIN LINKED KINASE; NERVE CELL ADHESION MOLECULE; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN;

ADULT; ARTICLE; CANCER INHIBITION; CASE REPORT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TONGUE CANCER; TUMOR XENOGRAFT;

GASTROPODA;

EID: 84879884856     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2022.113391     Document Type: Erratum

References (46)

1. Warnakulasuriya S. Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral. Oncol. 2010, 46:407-410.
2. Bello I.O., Soini Y., Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II). Oral. Oncol. 2010, 46:636-643.
3. Wickstrom S.A., Lange A., Montanez E., Fassler R. The ILK/PINCH/parvin complex: the kinase is dead, long live the pseudokinase!. EMBO. J. 2010, 29:281-291.
4. Qin J., Wu C. ILK: a pseudokinase in the center stage of cell-matrix adhesion and signaling. Curr. Opin. Cell. Biol. 2012, 24:607-613.
5. Zervas C.G., Psarra E., Williams V., Solomon E., Vakaloglou K.M., Brown N.H. A central multifunctional role of integrin-linked kinase at muscle attachment sites. J. Cell. Sci. 2011, 124:1316-1327.
6. Xie J., Lu W., Gu R., Dai Q., Zong B., Ling L., Xu B. The impairment of ILK related angiogenesis involved in cardiac maladaptation after infarction. PloS one 2011, 6:e24115.
7. Chan J., Ko F.C., Yeung Y.S., Ng I.O., Yam J.W. Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PloS one 2011, 6:e16984.
8. Papanikolaou S., Bravou V., Gyftopoulos K., Nakas D., Repanti M., Papadaki H. ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion. Histopathology 2010, 56:799-809.
9. Watzka S.B., Posch F., Pass H.I., Huflejt M., Bernhard D., Hannigan G.E., Muller M.R. Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2011, 142:384-389.
10. Kalra J., Warburton C., Fang K., Edwards L., Daynard T., Waterhouse D., Dragowska W., Sutherland B.W., Dedhar S., Gelmon K., Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 2009, 11:R25.
11. Wang M., Li C., Nie H., Lv X., Qu Y., Yu B., Su L., Li J., Chen X., Ju J., Yu Y., Yan M., Gu Q., Zhu Z., Liu B. Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett. 2012, 586:2382-2388.
12. Foroni C., Broggini M., Generali D., Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer. Treat. Rev. 2012, 38:689-697.
13. Tiwari N., Gheldof A., Tatari M., Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin. Cancer. Biol. 2012, 22:194-207.
14. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
15. Chaw S.Y., Abdul Majeed A., Dalley A.J., Chan A., Stein S., Farah C.S. Epithelial to mesenchymal transition (EMT) biomarkers - E-cadherin, beta-catenin, APC and Vimentin - in oral squamous cell carcinogenesis and transformation. Oral. Oncol. 2012.
16. Sakamoto K., Imanishi Y., Tomita T., Shimoda M., Kameyama K., Shibata K., Sakai N., Ozawa H., Shigetomi S., Fujii R., Fujii M., Ogawa K. Overexpression of SIP1 and downregulation of E-cadherin predict delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma after partial glossectomy. Ann. Surg. Oncol. 2012, 19:612-619.
17. Sun L., Yao Y., Liu B., Lin Z., Lin L., Yang M., Zhang W., Chen W., Pan C., Liu Q., Song E., Li J. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012, 31:432-445.
18. Gao J., Zhu J., Li H.Y., Pan X.Y., Jiang R., Chen J.X. Small interfering RNA targeting integrin-linked kinase inhibited the growth and induced apoptosis in human bladder cancer cells. Int. J. Biochem. Cell. Biol. 2011, 43:1294-1304.
19. Younes M.N., Yigitbasi O.G., Yazici Y.D., Jasser S.A., Bucana C.D., El-Naggar A.K., Mills G.B., Myers J.N. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head. Neck. Surg. 2007, 133:15-23.
20. He R.G., Xu X.Q., Zhou X.J., Zhang X.L., Qiu W.L., et al. The establishment and some biological characteristics of a squamous cell cancer cell line of the human tongue (TCA 8113). Tumor 1983, 3:97-100.
21. Wu J.Z., Chen J.Y., Li F., Li Y., Zhang H. Establishement of a metastatic cell line from brain metastasis induced by injection of tongue cancer Tca8113 cells in nude mouse. J. Pract. Stomatol. 1999, 6:152-153.
22. Del Nogal M., Luengo A., Olmos G., Lasa M., Rodriguez-Puyol D., Rodriguez-Puyol M., Calleros L. Balance between apoptosis or survival induced by changes in extracellular-matrix composition in human mesangial cells: a key role for ILK-NFkappaB pathway. Apoptosis: Int. J. Program. Cell Death 2012, 17:1261-1274.
23. Papachristou D.J., Gkretsi V., Rao U.N., Papachristou G.I., Papaefthymiou O.A., Basdra E.K., Wu C., Papavassiliou A.G. Expression of integrin-linked kinase and its binding partners in chondrosarcoma: association with prognostic significance. Eur. J. Cancer. 2008, 44:2518-2525.
24. McDonald P.C., Fielding A.B., Dedhar S. Integrin-linked kinase--essential roles in physiology and cancer biology. J. Cell. Sci. 2008, 121:3121-3132.
25. Fielding A.B., Dobreva I., McDonald P.C., Foster L.J., Dedhar S. Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization. J. Cell. Biol. 2008, 180:681-689.
26. Sakai T., Li S., Docheva D., Grashoff C., Sakai K., Kostka G., Braun A., Pfeifer A., Yurchenco P.D., Fassler R. Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation. Genes Dev. 2003, 17:926-940.
27. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796:75-90.
28. Shin S.Y., Rath O., Zebisch A., Choo S.M., Kolch W., Cho K.H. Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer. Res. 2010, 70:6715-6724.
29. Acloque H., Thiery J.P., Nieto M.A. The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. EMBO. Rep. 2008, 9:322-326.
30. Araki K., Shimura T., Suzuki H., Tsutsumi S., Wada W., Yajima T., Kobayahi T., Kubo N., Kuwano H. E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br. J. Cancer. 2011, 105:1885-1893.
31. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
32. Valacca C., Bonomi S., Buratti E., Pedrotti S., Baralle F.E., Sette C., Ghigna C., Biamonti G. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J. Cell. Biol. 2010, 191:87-99.
33. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 2007, 7:415-428.
34. Olmeda D., Montes A., Moreno-Bueno G., Flores J.M., Portillo F., Cano A. Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. Oncogene 2008, 27:4690-4701.
35. Branch K.M., Hoshino D., Weaver A.M. Adhesion rings surround invadopodia and promote maturation. Biol. Open 2012, 1:711-722.
36. McDonald P.C., Oloumi A., Mills J., Dobreva I., Maidan M., Gray V., Wederell E.D., Bally M.B., Foster L.J., Dedhar S. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer. Res. 2008, 68:1618-1624.
37. Koul D., Shen R., Bergh S., Lu Y., de Groot J.F., Liu T.J., Mills G.B., Yung W.K. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol. Cancer. Ther. 2005, 4:1681-1688.
38. Doble B.W., Woodgett J.R. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 2007, 185:73-84.
39. McPhee T.R., McDonald P.C., Oloumi A., Dedhar S. Integrin-linked kinase regulates E-cadherin expression through PARP-1. Dev. Dynam.: Off. Pub. Am. Assoc. Anatomists 2008, 237:2737-2747.
40. Maseki S., Ijichi K., Tanaka H., Fujii M., Hasegawa Y., Ogawa T., Murakami S., Kondo E., Nakanishi H. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br. J. Cancer. 2012, 106:1196-1204.
41. Li J., Zhou B.P. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011, 11:49.
42. Kalra J., Sutherland B.W., Stratford A.L., Dragowska W., Gelmon K.A., Dedhar S., Dunn S.E., Bally M.B. Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene 2010, 29:6343-6356.
43. Serrano I., McDonald P.C., Lock F.E., Dedhar S. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFbeta-1-induced epithelial-mesenchymal transition (EMT). Oncogene 2012.
44. Sabe H. Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor beta signalling. J. Biochem. 2011, 149:633-639.
45. Micalizzi D.S., Farabaugh S.M., Ford H.L. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J. Mammary. Gland. Biol. Neoplasia 2010, 15:117-134.
46. Muramatsu M., Yamamoto S., Osawa T., Shibuya M. Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer. Res. 2010, 70:8211-8221.